文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

加巴喷丁辅助吗啡治疗儿童严重神经病理性或混合性疼痛:新型液体制剂的安全性、药代动力学与疗效评估——随机对照试验研究方案

Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-01-15

主要终点为治疗12周后平均疼痛评分,次要终点包括应答率、突破性疼痛次数、救援干预次数、无痛天数、生活质量等。

要点

  • 加巴喷丁在儿童神经病理性疼痛中属超说明书用药,其疗效与安全性此前未经证实。
  • 加巴喷丁目标累积剂量为45至63 mg/kg/日(依年龄而定),联合吗啡治疗12周。

核心结论

  • 期望提供证据表明吗啡联合加巴喷丁较单用吗啡镇痛更优且安全,并确认推荐儿童剂量。

研究设计与样本

  • 受试者按三个年龄组分层随机,接受加巴喷丁液体制剂或安慰剂,均联合吗啡,治疗12周。
  • 随机化前设短期洗脱期,治疗以3周滴定期开始,治疗后药物在4周内逐渐减量。

关键数值与推荐

  • 主要终点为治疗组间平均疼痛评分,取研究终点访视(V10)前3天每日两次测量的平均值,采用年龄适配疼痛量表(FLACC、FPS-R、NRS)。
  • 加巴喷丁目标累积剂量为45至63 mg/kg/日,依年龄而定。
  • 次要结局包括疼痛量表降低30%的应答者百分比、突破性疼痛次数、救援干预次数、无痛天数、退出率、生活质量(PedsQL)和治疗可接受性。
  • 疗效分析在意向治疗基础上进行,结局于治疗12周达最佳加巴喷丁剂量后的研究终点访视测量。

临床怎么用

  • 若试验达到主要终点,可为儿童严重慢性神经病理性或混合性疼痛联合使用加巴喷丁与吗啡提供证据,并支持该液体制剂儿科剂量的确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults. Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic pain, its use is off-label. Its efficacy and safety in this context have never been shown. The aim of this trial is to compare gabapentin with placebo as add-on to morphine for the treatment of severe chronic mixed or neuropathic pain in children. This trial is part of the European Union Seventh Framework Programme project Gabapentin in Paediatric Pain (GAPP) to develop a pediatric use marketing authorization for a new gabapentin suspension. METHODS/DESIGN: The GAPP-2 study is a randomized, double-blind, placebo-controlled, multicenter superiority phase II study in children with severe chronic neuropathic or mixed pain. Its primary objective is to evaluate the efficacy of a gabapentin liquid formulation as adjunctive therapy to morphine. Sixty-six eligible children 3 months to 18 years of age with severe pain (pain scores ≥ 7), stratified in three age groups, will be randomized to receive gabapentin (to an accumulating dose of 45 to 63 mg/kg/day, dependent on age) or placebo, both in addition to morphine, for 12 weeks. Randomization will be preceded by a short washout period, and treatment will be initiated by a titration period of 3 weeks. After the treatment period, medication will be tapered during 4 weeks. The primary endpoint is the average pain scores in the two treatment groups (average of two measures each day for 3 days before the end-of-study visit [V10] assessed by age-appropriate pain scales (Face, Legs, Activity, Cry, Consolability scale; Faces Pain Scale-Revised; Numeric Rating Scale). Secondary outcomes include percentage responders to treatment (subjects with 30% reduction in pain scale), number of episodes of breakthrough pain, number of rescue interventions, number of pain-free days, participant dropouts, quality of life (Pediatric Quality of Life Inventory), and acceptability of treatment. Outcomes will be measured at the end-of-study visit after 12 weeks of treatment at the optimal gabapentin dose. Groups will be compared on an intention-to-treat basis. DISCUSSION: We hope to provide evidence that the combination of morphine and gabapentin will provide better analgesia than morphine alone and will be safe. We also aim to obtain confirmation of the recommended pediatric dose. TRIAL REGISTRATION: EudractCT, 2014-004897-40 . Registered on 7 September 2017. ClinicalTrials.gov, NCT03275012 . Registered on 7 September 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. de Leeuw TG, Mangiarini L, Lundin R, et al. Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30646965. doi:10.1186/s13063-018-3169-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。